Clinical trials show that combined BRAF/MEK inhibition (e.g., dabrafenib + trametinib) leads to rapid tumor regression in BRAF‐mutant ATC, prompting guideline recommendations for immediate molecular or immunohistochemical testing [191]. Here, BRAF is linked to neoplasm.